Nonalcoholic fatty liver disease (NAFLD) and hepatitis C virus (HCV)-related liver disease
are common in the general population, but their concurrence is 2-to 3-fold higher than would …

Non‐alcoholic fatty liver disease (NAFLD) is an important complication of the metabolic
syndrome, which is becoming an increasingly common cause of chronic liver disease …

The mechanisms for progressive fibrosis and exacerbation by steatosis in patients with
chronic hepatitis C (HCV) are still unknown. We hypothesized that proliferative blockade in …

The prevalence of fatty liver is rising in association with the global increase in obesity and
type 2 diabetes. In the past, simple steatosis was regarded as benign, but the presence of …

The aim of this study was to determine if body mass index (BMI) was an independent
predictor of response to antiviral treatment in patients with chronic hepatitis C. A …

Background: Insulin resistance is a frequent feature of chronic hepatitis C. Whether insulin
resistance could be the cause or consequence of steatosis and fibrosis is unknown. The …

Background: Steatosis occurs in more than 50% of patients with chronic hepatitis C and is
associated with increased hepatic fibrosis. In many of these patients the pathogenesis of …

Background and aims: Steatosis, a frequent histological finding in patients with chronic
hepatitis C (CHC), has been suggested to influence liver fibrosis progression. The aim of the …

OBJECTIVE: Hepatitis C virus (HCV) disease progression is variable. Identification of factors
predictive of rapid progression is an important goal for improving patient management. The …

Background/Aims: Steatosis is common in patients with hepatitis C virus (HCV) infection. Its
influence on disease progression is only partially understood. The aim of this study was to …